EGCG reducing the susceptibility to cholesterol gallstone formation through the regulation of inflammation - 26/11/08
Corresponding author. State Key Laboratory of Bioreactor Engineering & School of Pharmacy, East China University of Science and Technology, Shanghai 200237, PR China. Tel./fax: +86 21 64252044.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
In order to investigate whether (−)-Epigallocatechin-3-gallate (EGCG) can reduce the susceptibility to cholesterol gallstone formation in vivo, cholesterol gallstones mouse model was established with lithogenic diet. Compared with the Model group, the administration of EGCG (40mgkg−1d−1 and 80mgkg−1d−1, i.g., respectively) significantly reduced the gallstone formation rates and the serum lipid levels, also maintained the body weight at a relatively low level. Results of the microarray profiling assay showed the anti-inflammation effect of EGCG underlying affecting the hepatic metabolic pathway of cholesterol. Additionally, the expression of nuclear factor-κB (NF-κB) was down-regulated and the expression of peroxisome proliferator activated receptor gamma (PPARγ) was up-regulated after the treatment of EGCG. Also, the expression of CYP7A1 was up-regulated after the treatment of EGCG.
In conclusion, the findings of this study implied that EGCG can effectively reduce the susceptibility to cholesterol gallstone formation through the regulation of inflammation.
Le texte complet de cet article est disponible en PDF.Keywords : (−)-Epigallocatechin-3-gallate (EGCG), Cholesterol gallstone, Anti-inflammation effect, Cholesterol metabolic
Plan
Vol 62 - N° 10
P. 677-683 - décembre 2008 Retour au numéro
Article précédent
- Inhibition of DNA methyltransferase activity upregulates Fyn tyrosine kinase expression in Hut-78 T-lymphoma cells
- A. Kozłowska, P.P. Jagodziński
- Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials
- Nashira Campos Vieira, Christine Herrenknecht, Joel Vacus, Alain Fournet, Christian Bories, Bruno Figadère, Laila Salmen Espindola, Philippe M. Loiseau
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?